Pennsylvaniassa toimiva JBS Science kertoi tänään saaneensa 3 miljoonan dollarin Bridge Award -palkinnon Small Business Innovation Research IIB:lle National Cancer Institutelta. Yritys kehitti ensimmäisen nestemäisen biopsiatuotteen, joka on virtsan DNA-seulonta varhaisen maksasolusyövän (HCC) varalta.
Despite the monitoring plan for high-risk groups (such as patients with chronic hepatitis, cirrhosis, and fatty liver disease), HCC is usually only discovered at an advanced stage. But if HCC can be detected early, the survival rate can be as high as 40%. Although the detection of the biomarker serum alpha-fetoprotein (AFP) currently shows sensitivity, there is still much room for improvement in the early screening of maksa syöpä. The technology developed by JBS to separate cancer-derived DNA in urine, as well as a special PCR detection method, can more accurately and sensitively detect circulating kasvain DNA biomarkers for liver cancer. In a blind pre-validation study, the company stated that if serum AFP is added, the sensitivity of the method will increase to 89%.
JBS sanoi, että se on tehnyt yhteistyötä James Hamiltonin Johns Hopkins University Medical Centeristä ja Hie-Won Hannin kanssa Thomas University Hospitalista edistääkseen maksasyövän virtsatestin kehitystä.
https://www.genomeweb.com/molecular-diagnostics/jbs-science-awarded-3m-commercialize-liver-cancer-screening-test#.W62TzNczbIU
